Abstract
The reaction of cyanoacetylhydrazine (1) with 3-(2-bromoacetyl)-2H-chromen-2-one (2) in 1,4-dioxan gave the hydrazidehydrazone derivative (3). The latter compound was cyclized to the 1,3,4-oxadiazine derivative 4, its 4-bromo derivative underwent a series of cross coupling reactions together with [4+2] cycloaddition reactions with either acrylonitrile or ethyl acrylate to afford the pyran derivatives 10a and 10b, respectively. The antitumor evaluation of the newly synthesized products against three cancer cell lines, namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268) were recorded. Four of the synthesized compounds namely 7c, 10a, 11a and 12b showed high inhibitory effects. Moreover, the anti-leishmanial activity of the newly synthesized product was tested on Leishmania donovani amastigotes showed that some compounds have high activity.
Keywords: Cross coupling, Hydrazide-hydrazone, 1, 3, 4-oxadiazine, coumarin, Anti-tumor.
Current Organic Chemistry
Title:Design, Synthesis and Molecular Modeling Studies of Some Heterocyclic Compounds Derived from the Suzuki-coupling of 6-bromo-1,3,4-oxadiazine Together with their Antitumor and Anti-leishmanial Evaluations
Volume: 17 Issue: 17
Author(s): Rafat M. Mohareb, Sherif M. Sherif and Adel Abou Elkair
Affiliation:
Keywords: Cross coupling, Hydrazide-hydrazone, 1, 3, 4-oxadiazine, coumarin, Anti-tumor.
Abstract: The reaction of cyanoacetylhydrazine (1) with 3-(2-bromoacetyl)-2H-chromen-2-one (2) in 1,4-dioxan gave the hydrazidehydrazone derivative (3). The latter compound was cyclized to the 1,3,4-oxadiazine derivative 4, its 4-bromo derivative underwent a series of cross coupling reactions together with [4+2] cycloaddition reactions with either acrylonitrile or ethyl acrylate to afford the pyran derivatives 10a and 10b, respectively. The antitumor evaluation of the newly synthesized products against three cancer cell lines, namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268) were recorded. Four of the synthesized compounds namely 7c, 10a, 11a and 12b showed high inhibitory effects. Moreover, the anti-leishmanial activity of the newly synthesized product was tested on Leishmania donovani amastigotes showed that some compounds have high activity.
Export Options
About this article
Cite this article as:
Mohareb M. Rafat, Sherif M. Sherif and Elkair Abou Adel, Design, Synthesis and Molecular Modeling Studies of Some Heterocyclic Compounds Derived from the Suzuki-coupling of 6-bromo-1,3,4-oxadiazine Together with their Antitumor and Anti-leishmanial Evaluations, Current Organic Chemistry 2013; 17(17) . https://dx.doi.org/10.2174/13852728113179990037
DOI https://dx.doi.org/10.2174/13852728113179990037 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The link between Hepatic Vitamin A Metabolism and Nonalcoholic Fatty Liver Disease
Current Drug Targets D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism Stereoselective Metabolic and Pharmacokinetic Analysis of the Chiral Active Components from Herbal Medicines
Current Pharmaceutical Analysis Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) Does Cyclic Dependent Kinase 5 Play a Significant Role in Determination of Stroke Outcome? Possible Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry The JAK-STAT Pathway: A Therapeutic Target in Hematological Malignancies
Current Cancer Drug Targets Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Involvement of Heat Shock Proteins and Related Molecules in the Resistance to Therapies in Breast and Gynecologic Cancer
Current Cancer Therapy Reviews UPA and PAI-1 Analysis from Fixed Tissues – New Perspectives for a Known Set of Predictive Markers
Current Medicinal Chemistry Synthesis and Evaluation of Cytotoxicity of Novel Coumarin Peptide Alcohol Derivatives
Medicinal Chemistry Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect
Current Medicinal Chemistry Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets